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PTCA was successful (TIMI flow 3) in 39 IRA and in 47 other segments of
non IRA; in one pt the guide wire did not cross the lesion and the remaining pt
had diffuse disease. No major complications and no pts required emergency
cxxonaty bypass surgery (CABG). In Gr 2, TIMI flow 0/1 was found in 42
pts. Successful repetfusion was achieved in 28 pts and 14 pts had treatment
failure. Hospital stay was significantly shorter in Gr 1 than Gr 2 (4.5 & 2.3
V 8.9 + 4.1 days, respectively, p = 0.0001). At 8 months (me: there was no
death in Gr 1, one pt had recurrent ischaemia and one pt had CABG. In Gr
2, four pts died, 22 had recurrent ischaemia, 10 required PTCA and 11 pts
had CABG. Exercise variables were significantly different at 6 weeks but not
at 8 mos when 21 pts in Gr 2 had revaacularisation. Thus, primary PTCA
in pts with AMI is a safe and effective approach to achieve a higher rate of
patency and early reperfusion of IRA, a lower incidence of recurrent myocar-
dial ischaemia and a significantly shorter stay in hospital than thrombolysis.
Such benefits were sustained at 8 months with significantly less pts requiring
revascularisation in Gr 1.
D971 11 IntracoronaryStantTherapyEnhanceaLuminalDiameterandRaduceaReaidualStenoaiaInA
Subsetof PatientaWithAcuteMyocardialInfarction
R.S. Wright, B.D. Nunez, G.S. Reeder, S.L. Kopecky, K.N. Garrat. Mayo
Clinic Rochester, MN, USA
The utility of percutaneous revascularization in acute myocardial infarction
(Ml) has been broadened by coupling coronary stent (CS) placement with
percutaneous transluminal coronaty angioplasty (PTCA). The risks and ben-
efits of CS placement remain unknown. We studied 41 patients receiving
CS+PTCAforacute Ml and compared them to 41 matched controls (forage,
gender, infarct related artery) who were treated with PTCA for acute ML
There were no overall differences between CS+PTCA vs PTCA alone with
regard to procedural success (93% VS90Yo),in-hospital mOrtality(O%vs 5%),
l-year mortality (6% vs 14%), early EF (61 l 10% vs 63 + 14%), need for
bypass surgery(i’%vs5Yo)and need for repeat procedure atone year (18%
vs 17%), all p = ns. The group treated with CS+PTCA had greater minimal
Iuminal diameter (2.40 * 0.6 mm vs 1.40 * 0.7, p < 0.05) and a reduced
residual stenosis (19 l IIYo vs 49 * 21%, p -= 0.05) following CS+PTCA
then after the PTCA.
These date demonstrate that use of CS+PTCA is safe, effective and
associated with an excellent outcome at one year. Furthermore, these date
suggest that there may be a benefit in a subset of patients with regard
to reduced residual stenosis and enhanced Iuminal diameter following CS
placement than with PTCA alone.
~] Direc~AngioP,a.tY(pTCA)for MYocardia,,nfarction
ins CentreWithSurgicalBack-up220MileaAway
J.M. Elliott, A.M. Richards, K. Smitheran, D.W. Smyfh. Christchurch
Hospital, Christchurch, New Zealand
Direct PTCA improves outcome in selected patients with acute myooardial
infarction. The need for surgical back-up is debated. We have no resident
surgical programme but provide coronary care facilities for over 400,000
people in our city.
From June 1995 through June 1996 we performed 71 acute PTCA pro-
cedures, including 60 dire~ PTCASfor cardiogenic shock (n = 10), anterior
infarction (27), contraindication to thrombolysis (16), or SVG or stent throm-
bosis (7), and 11 rescue PTCA’Sfor clinical evidence of failed thrombolysis.
Mean age was 59 + 12 years, 62% were men, 24% had previous Ml, and
21% were Killip Class 3or4. Median time from decision to opening the artery
(TIMI 3flow by flow velocity) was 1.2 (1.0=1.5 interquartile range)h, and total
time from onset of pain to TIMI 3 flow was 3.5 (1.5-4.7)h.
Procedural success (TIMI 3flow, residual stenosis <50% and absence of
procedural death) was achieved in 93% of non-shocked patients with direct
or rescue angioplasty, in 97% of the 37 patients who would have been eligible
for the PAMI Study, and in 6 of 10 with cardiogenic shock (with 4 discharged
alive). Mean final diameter StenOSiSwas 29 + 14Y0.Intra-coronaty stents
were used in 21 patients, intracoronary thrombolytics in 2, and Abciximab
(ReoPro) in 12 patients. Mean hospital stay for the whole group was 5.6+
2.2 days. Four threatened re-infarctions in-hospital were treated by re PTCA
with no new enzyme rise.
At 3 months follow-up in 44 patients, there were no deaths or reinfarction,
angina had recurred in 6, with redo PTCA in 2 and bypass surgery in 4.
The remainder have no or CCS Class I angina. These data confirm that
emergency PTCA ean be performed safely and effectively by well trained
operators in centres with remote surgical back-up.
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m] Relati.eSafeWofShoti-termantian~inal
MedicationWithdrawal:Relevancato ClinicalTrials
W. Jiang, J.A. Blumenthal, M.W. Hanson, R.E. Coleman, D.J. Frid,
R.A. Waugh, J.J. Morris, C.M. O’Connor. Duke University Medical Centec
Durham, NC, USA
Because fl-blocker (fI-b) and calcium-channel blocker (Ca-b) withdrawal may
affect safety and ischemic assessments in clinical trials, we examined the
safety of short-term withdrawal and its effeds on angina and hemodynamic
responses to stress testing. One hundred and thirty-six CAD patients with-
drew from fkb (Group 1), Ca-b (Group 2), both (Group 3) or neither (Group
4), and long-acting nitrates (equally distributed among groups), and under-
went 48-hour Helter monitoring and an exercise test. Withdrawal duration
was 140 h for long-acting and 116 h for short-acting drugs. No admissions
resulted from withdrawal symptoms. Pre-withdrawal, Groups 1 and 3 had
significantly lower blood pressure (BP, p = 0.002) and heari rate (HR, p =
0.001) than Groups 2 and 4; post-withdrawal, all groups had similar BP and
HR at rest and during stress testing. Ischemic activity (TMI in mV/min) was
not significantly different among groups (table).
Pre-Withdrawal Post-Withdrawal PeakExercise
Groin 1 2 3 4 1 2 3 4 I P ?, ~
SBP 131 13S 126 136 145 149 141 141 211 215 206 209
DBP 82 83 76 65 S6 84 85 86 107 106 104 105
HR 80 87 80 67 75 73 73 74 140 134 137 143
TMI - - - - 54 40 48 37 61 75 72 60
Short-term fl-biocker and calcium-channel blocker withdrawal appeared
to be safe and was not associated with increased iechemic activity or ab-
normal hemodynamic responses to stress; thus, it may be eonaidered when
evaluating new therapeutics.
-] A.tiiachemi.EffactaOfBeta-B,OckadeWitfI
Betaxololin PatientsWithSilentIschemiaand
PeripheralVaacularDisaaae
P.C.Deedwania, E.V.Carbajal, M. Martinuson, J. Oakley. VAkfC/UCSF
School of Medicine, Fresno, CA, USA
Several previous studies have demonstrated that silent ischemia detected
by ambulatory ECG nionitoring (AEM) is predictive of increased risk of peri-
operative cardiac event8 in patients undergoing peripheral vascular surgery.
Myocardial revascularization is frequently recommended in patients with
silent ischemia prior to vascular surgery in an effort to reduce the risk of peri-
operative cardiac events. However, such an approach is costly and may not
be necessary if antiischemic drug therapy can effectively reduce the risk of
myocardial ischemia. Accordingly, we prospectively evaluated the effects of
a long-acting cardioselective beta-blocker, betexolol (20 mg/d) in 30 patients
with peripheral vascular disease and 21 ischemic episode on 48 h AEM
performed during preoperative evaluation and who had repeat 48 h AEM
after betexolol therapy. At baseline the mean number of ischemic episodes
was 3.9 + 2.7/48 h and was reduced by 0.4 + 0.8/48 h (90% reduction, p
< 0.0001) during betaxolol, The average duration of ischemia was 136 l
148 minf46 h and was reduced significantly (p= 0.0002) by 87% to 17• 30
rein/48 h after betaxolol, The average duration per ischemic event was also
significantly reduced by 637. (33 min vs 5.5, p < 0.0001) during treatment
with betaxolol.
Cone/usiorr:The results of this study demonstrate that preoperative treat-
ment with betaxolol can effectively suppress silent ischemic episodes in
patients with peripheral vascular disease. These date indicate that antiis-
chemic therapy with effective beta-blockade might be beneficial in reducing
the risk of perioperative cardiac events in patients undergoing major vascular
surgery.
